Clinical Trial Update: CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 clinical trial evaluating CD19-BAFF CAR-T cells for relapsed or refractory B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19-BAFF CAR-T Cells (CD19-BAFF chimeric antigen receptor T cells)

Snippet

Sponsor: Zhejiang University | Conditions: Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell | EARLY_Phase 1 | Status: RECRUITING